We're excited to be mentioned in this Nature Biotechnology article!

Great work Carter Grochala on this Nature Communications paper that came out last month! pubmed.ncbi.nlm.nih.gov/36914658/

Arpeggio is changing the way we discover drugs. Check out our AACR poster outlining how we used high-throughput transcriptomics to discover a novel GPX4 inhibitor!

Patient selection is a major hurdle in the drug development process. Check out our AACR poster describing the use of enhancer RNA signatures to define patient populations that will respond to our novel GPX4 inhibitor!

Find the team presenting on our discovery of a novel GPX4 inhibitor using high-throughput transcriptomics! (Section 17 #9) We're having a great time attending sessions and making new connections at AACR 🧬

Help Reo Yoo support Sophie’s Neighborhood! Buy tickets to the event on May 7th or donate directly - see below for details! Hope to see you there!

It’s important – personally as well as professionally – not to put people on a pedestal. When we assume person X or Y has had so much success that they couldn’t possibly want to talk to *us*, we subtly rob them of their humanity. Everyone is more than the net sum of their...1/9

Our CEO, Joey Azofeifa, will be talking at the BIO International Convention about how we're developing therapies for diseases driven by transcription factors! Please check out his talk on Wednesday June 7th at 4:15p ET in Room 104B! #StandUpForScience #BIO2023

Awesome job to Dave Simpson for repping Arpeggio yesterday at the CU Boulder 🦬 Core Facilities Open House and Local Industry Fair!

We’re incredibly excited to publish the inaugural edition of the Decoding Bio Snapshot. Several months in the making, it profiles 40 companies operating at the intersection of computation and biology, ranging from pre-seed to publicly traded. snapshot.decodingbio.com

Because the average biotech CEO is a 54-year old guy named Mike who isn’t actually a nerd

How inspiring that we've made GS's Impact100, an annual list of the world's 100 most promising impact #startups - this list exists to give you energy, hope, and positive inspiration! #100waystofixthefuture #NASDAQ

Human trampling affects alpine plants differently, which has important conservation implications 🌱🦶🏔️Delighted to share my first publication from my Swiss National Science Foundation postdoctoral fellowship!doi.org/10.3390/plants…

I am increasingly -tive biotech. (Consistent for past 3 years) Investors are creating their own problems. They do not want to take risks on novel science. Instead supporting IPOs of me-too drugs and targets. Then they are left with a sea of competition with marginal benefit.

We are proud to be selected by the Endpoints News editorial team as one of the most promising and ambitious #biotech startups! We’re grateful for the recognition of what we’ve built so far and where we are headed next: the clinic in 2024! endpts.com/the-endpoints-…

Many professional biotech investors and operators think that rare disease parents are just a bunch of moms and dads who could never become biotech CEOs. It’s true that most parents aren’t founders. But some are! And when lightning strikes them, they go to work finding cures.

Strong Arpeggio representation at SLAS with Tim Read and Casey Pham both presenting today in collaboration with Beckman Coulter Life Sciences and Biosero 👏 Be sure to connect with our team if you're there!

We’re also very excited to present our NRF2 degrader at AACR! This amazing small molecule leads to regression of aggressive lung adenocarcinoma tumors in vivo and was discovered using our AI + transcriptomics platform. Stop by on April 8th from 1:30-5:00, Section 52, Board 15.

Cellarity MIT Dept of BE UW Genome Sciences Novartis Thank you, Cellarity, for featuring our NRF2 program as part of your third annual symposium! Watch Joey Azofeifa 's presentation: “Massively high throughput transcriptomics discovers a molecular glue degrading NRF2 in lung cancer” at 12:45 ET. lnkd.in/ddxuVCt5

So when I hear demagogues denounce "Big Pharma," I append my own branding: "Big Pharma. The people who rescue children from leukemia." END